Skip to content Provide accessibility feedback
By using the Volpara website you accept our use of cookies. Here’s our privacy statement.
Breast Health
Lung Health
Magnifying glass Search

Artificial intelligence in radiology: 100 commercially available products and their scientific evidence

van Leeuwen, Schalekamp, Rutten, van Ginneken, de Rooij

“The overview included 100 CE-marked AI products from 54 different vendors. For 64/100 products, there was no peer-reviewed evidence of its efficacy.”

Volpara had the most scientific papers of all breast radiology AI software reviewed in the study.

Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue

Shermis, Wilson, Doyle, Martin, Merryman, Kudrolli, Brenner

“When incorporated into a community-based clinical practice environment, molecular breast imaging yielded a high incremental cancer detection rate of 7.7% at an acceptable radiation dose. These results show the utility of molecular breast imaging as a
supplementary screening tool to mammography for women with dense breasts.”

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial

Saadatmand, Geuzinge, Rutgers, Mann, van Zuidewijn, Zonderland, Tollenaar, Lobbes, Ausems, van 't Riet, Hooning, Mares-Engelberts, Luiten, Heijnsdijk, Verhoef, Karssemeijer, Oosterwijk, Obdeijn, de Koning, Tilanus-Linthorst

“MRI screening detected cancers at an earlier stage than mammography. The lower number of late-stage cancers identified in incident rounds might reduce the use of adjuvant chemotherapy and decrease breast cancer-related mortality.”

Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis

Gray, Donten, Karssemeijer, van Gils, Evans, Astley, Payne

“The base-case analysis, supported by probabilistic sensitivity analysis, suggested that the risk stratified NBSPs (risk 1 and risk-2) were relatively cost-effective when compared with the current UK NBSP, with incremental cost-effectiveness ratios of £16,689 per QALY and £23,924 per QALY, respectively.”

What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420)

French, Astley, Brentnall, Cuzick, Dobrashian, Duffy, Gorman, Harkness, Harrison, Harvie, Howell, Jerrison, Machin, Maxwell, McWilliams, Payne, Qureshi, Ruane, Sampson, Stavrinos, Thorpe, Ulph, van Staa, Woof, Evans

“Once a clear mammogram result has been provided, a risk feedback letter is generated based on the answers participants give in their questionnaire and mammographic breast density (calculated from uploaded raw data by Volpara systems) … The risk feedback letter will inform women that they are at “high” (≥8% 10-year risk), “moderate” (≥5% but < 8% 10-year risk), “average” (≥ 2% but < 5% 10-year risk), or “below average” risk (< 2% 10-year risk).”